ICU Medical (ICUI)
(Delayed Data from NSDQ)
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Zacks News
ICU Medical (ICUI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.85% and 6.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ICU Medical
by Zacks Equity Research
ICU Medical, Inc. (ICUI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ICU Medical (ICUI) Misses Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -4.78% and 1.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 18.35% and 4.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q1 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
by Zacks Equity Research
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View
by Zacks Equity Research
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.
Thermo Fisher (TMO) Beats on Q1 Earnings, Raises '19 View
by Zacks Equity Research
Thermo Fisher (TMO) reports strong Laboratory Products and Services performance, flaunting robust global demand.
Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise
by Zacks Equity Research
Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.
Merit Medical (MMSI) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.
Stryker (SYK) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.
Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.
Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice
by Zacks Equity Research
ICU Medical (ICUI) could produce exceptional returns because of its solid growth attributes.
Baxter (BAX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice
by Zacks Equity Research
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.